The single-target problem

For thirty years, the hair-loss field has been organized around single-target thinking. Minoxidil acts on one axis. Finasteride acts on one enzyme. Most peptide serums push a single growth factor pathway. Each of these products delivered real benefit — but each of them also plateaus, because the follicle sits inside a network of pathways that are all busy influencing each other. Silence one input and the network re-balances around the change, usually against the patient.
This is why the honest long-term result of any single-target product is stabilization at best, and why so many patients cycle through them looking for the combination that will actually hold.


